John A. Olson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
John A. Olson has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
C Daniel Mullins
Department of Pharmaceutical Health Services Research (Mullins), University of Maryland Medical Center, Baltimore, MD
1 shared publicationCheryl Schmidt
1 shared publicationCynthia X. Ma
1 shared publicationDean P. Edwards
1 shared publication- Elizabeth A. Streeten
Department of Medicine University of Maryland School of Medicine Baltimore Maryland USA
1 shared publication - Emily Ma
Department of Dermatology, University of Maryland School of Medicine , Baltimore, MD
1 shared publication
Latest Publications
- 3 November 2023
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 238 (2) , e1-e5
Combined Thyroid-Parathyroid Organ Transplantation: Demonstration of Technical Feasibility in a Perfused Cadaver Model
An abstract is unavailable. This article is available as a PDF only.
- 3 November 2023
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 238 (2) , e1-e5
Combined Thyroid-Parathyroid Organ Transplantation: Demonstration of Technical Feasibility in a Perfused Cadaver Model
An abstract is unavailable. This article is available as a PDF only.
- 4 November 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34, e3
Retro-orbital radiotherapy and systemic steroid therapy in thyroid eye disease: A ten-year audit against EUGOGO guidelines
- 4 November 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34, e3
Retro-orbital radiotherapy and systemic steroid therapy in thyroid eye disease: A ten-year audit against EUGOGO guidelines
- 28 February 2022
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 234 (4) , 521-528
Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma
Export BACKGROUND: Adjuvant therapy for most sentinel-node–positive (stage IIIA) melanoma may have limited clinical benefit for older patients given the competing risk of non-cancer death. The objective of this study is to model the clinical effect and cost of adjuvant therapy in stage IIIA melanoma across age groups. STUDY DESIGN: A Markov decision analysis model simulated the overall survival of patients with resected stage IIIA melanoma treated with adjuvant therapy vs observation. In the adjuvant approach, patients are modeled to receive adjuvant pembrolizumab (BRAF wild type) or dabrafenib/trametinib (BRAF mutant). In the observation approach, treatment is deferred until recurrence. Transition variables were derived from landmark randomized trials in adjuvant and salvage therapy. The model was analyzed for age groups spanning 40 to 89 years. The primary outcome was the number needed to treat (NNT) to prevent one melanoma-related death at 10 years. Cost per mortality avoided was estimated using Medicare reimbursement rates. RESULTS: Projections for NNT among BRAF wild type patients increased by age from 14.71 (age 40 to 44) to 142.86 (age 85 to 89), with patients in cohorts over the age of 75 having an NNT over 25. The cost per mortality avoided ranged from $2.75 million (M) (age 40 to 44) to $27.57M (age 85 to 89). Corresponding values for BRAF mutant patients were as follows: NNT 18.18 to 333.33; cost per mortality avoided ranged from $2.75M to $54.70M. CONCLUSION: Universal adjuvant therapy for stage IIIA melanoma is costly and provides limited clinical benefit in patients older than 75 years.
- 28 February 2022
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 234 (4) , 521-528
Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma
Export BACKGROUND: Adjuvant therapy for most sentinel-node–positive (stage IIIA) melanoma may have limited clinical benefit for older patients given the competing risk of non-cancer death. The objective of this study is to model the clinical effect and cost of adjuvant therapy in stage IIIA melanoma across age groups. STUDY DESIGN: A Markov decision analysis model simulated the overall survival of patients with resected stage IIIA melanoma treated with adjuvant therapy vs observation. In the adjuvant approach, patients are modeled to receive adjuvant pembrolizumab (BRAF wild type) or dabrafenib/trametinib (BRAF mutant). In the observation approach, treatment is deferred until recurrence. Transition variables were derived from landmark randomized trials in adjuvant and salvage therapy. The model was analyzed for age groups spanning 40 to 89 years. The primary outcome was the number needed to treat (NNT) to prevent one melanoma-related death at 10 years. Cost per mortality avoided was estimated using Medicare reimbursement rates. RESULTS: Projections for NNT among BRAF wild type patients increased by age from 14.71 (age 40 to 44) to 142.86 (age 85 to 89), with patients in cohorts over the age of 75 having an NNT over 25. The cost per mortality avoided ranged from $2.75 million (M) (age 40 to 44) to $27.57M (age 85 to 89). Corresponding values for BRAF mutant patients were as follows: NNT 18.18 to 333.33; cost per mortality avoided ranged from $2.75M to $54.70M. CONCLUSION: Universal adjuvant therapy for stage IIIA melanoma is costly and provides limited clinical benefit in patients older than 75 years.
- Open Access
- 1 March 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 4 (3) , 286
Invasive phaeochromocytoma presenting as a right atrial mass
- 1 March 2016
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 4 (3) , 286
Open AccessInvasive phaeochromocytoma presenting as a right atrial mass
- 2 January 2014
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 10 (1) , 123-126
All Things Digital. Ten Years in the Geospatial Time Continuum
- 2 January 2014
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 10 (1) , 123-126
All Things Digital. Ten Years in the Geospatial Time Continuum
- Open Access
- 2 October 2013
- Published by Taylor & Francis in The AAG Review of Books
- Vol. 1 (4) , 187-188
The GIS Guide to Public Domain Data
- 2 October 2013
- Published by Taylor & Francis in The AAG Review of Books
- Vol. 1 (4) , 187-188
Open AccessThe GIS Guide to Public Domain Data
- 13 September 2012
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 8 (3) , 290-294
Geography, GIS and Gaming: Learning Tools or Just for Fun?
- 13 September 2012
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 8 (3) , 290-294
Geography, GIS and Gaming: Learning Tools or Just for Fun?
- 20 September 2011
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 7 (3) , 377-381
Health-Related Geospatial Data and Social Media: Can You Harvest Geosocial Data?
(2011). Health-Related Geospatial Data and Social Media: Can You Harvest Geosocial Data? Journal of Map & Geography Libraries: Vol. 7, Part 2: Geographic Opportunities in Medicine, pp. 377-381.
- 20 September 2011
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 7 (3) , 377-381
Health-Related Geospatial Data and Social Media: Can You Harvest Geosocial Data?
(2011). Health-Related Geospatial Data and Social Media: Can You Harvest Geosocial Data? Journal of Map & Geography Libraries: Vol. 7, Part 2: Geographic Opportunities in Medicine, pp. 377-381.
- 31 December 2009
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 6 (1) , 76-78
Data as a Service: Are We in the Clouds?
(2009). Data as a Service: Are We in the Clouds? Journal of Map & Geography Libraries: Vol. 6, Preservation of Digital Geospatial Materials, pp. 76-78.
- 31 December 2009
- Published by Taylor & Francis in Journal of Map & Geography Libraries
- Vol. 6 (1) , 76-78
Data as a Service: Are We in the Clouds?
(2009). Data as a Service: Are We in the Clouds? Journal of Map & Geography Libraries: Vol. 6, Preservation of Digital Geospatial Materials, pp. 76-78.